|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2007-3-29
|
|
pubmed:abstractText |
Metformin is the 'drug-of-first-choice' in obese patients with type 2 diabetes mellitus (T2DM) due to its antihyperglycaemic and cardiovascular protective potentials. In non-obese patients with T2DM, insulin secretagogues are empirically used as first choice. In this investigator-initiated trial, we evaluated the effect of metformin vs. an insulin secretagogue, repaglinide on glycaemic regulation and markers of inflammation and insulin sensitivity in non-obese patients with T2DM.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adiponectin,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/C-Peptide,
http://linkedlifedata.com/resource/pubmed/chemical/C-Reactive Protein,
http://linkedlifedata.com/resource/pubmed/chemical/Carbamates,
http://linkedlifedata.com/resource/pubmed/chemical/Hemoglobin A, Glycosylated,
http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Metformin,
http://linkedlifedata.com/resource/pubmed/chemical/Piperidines,
http://linkedlifedata.com/resource/pubmed/chemical/repaglinide
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1462-8902
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
394-407
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17391168-Adiponectin,
pubmed-meshheading:17391168-Biological Markers,
pubmed-meshheading:17391168-Blood Glucose,
pubmed-meshheading:17391168-Body Weight,
pubmed-meshheading:17391168-C-Peptide,
pubmed-meshheading:17391168-C-Reactive Protein,
pubmed-meshheading:17391168-Carbamates,
pubmed-meshheading:17391168-Cross-Over Studies,
pubmed-meshheading:17391168-Diabetes Mellitus, Type 2,
pubmed-meshheading:17391168-Double-Blind Method,
pubmed-meshheading:17391168-Female,
pubmed-meshheading:17391168-Hemoglobin A, Glycosylated,
pubmed-meshheading:17391168-Humans,
pubmed-meshheading:17391168-Hyperglycemia,
pubmed-meshheading:17391168-Hypoglycemic Agents,
pubmed-meshheading:17391168-Insulin,
pubmed-meshheading:17391168-Male,
pubmed-meshheading:17391168-Metformin,
pubmed-meshheading:17391168-Middle Aged,
pubmed-meshheading:17391168-Patient Compliance,
pubmed-meshheading:17391168-Piperidines,
pubmed-meshheading:17391168-Prospective Studies,
pubmed-meshheading:17391168-Waist-Hip Ratio
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial.
|
|
pubmed:affiliation |
Steno Diabetes Center, Gentofte, Denmark. sqrl@steno.dk
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
